Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amprenavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CTSD | P07339 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.72 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.72 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amprenavir SCHEMBL11914014 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL1388821 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL20099148 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL5551513 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL3174937 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL34151 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL2671137 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL10276771 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL20451345 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 | |
| Amprenavir SCHEMBL12647024 | 1.00 | MLNR (1.00) | MLNRABCB11LMNACTSDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0977570-A1 | QUINOXALINE IN TRIPLE COMBINATION WITH PROTEASE INHIBITORS AND REVERSE TRANSCRIPTASE INHIBITORS AS MEDICINES FOR TREATING AIDS | BAYER AG (DE) | 2000-02-09 | — | — | EP | claimed |
| WO-1998032442-A1 | QUINOXALINE IN TRIPLE COMBINATION WITH PROTEASE INHIBITORS AND REVERSE TRANSCRIPTASE INHIBITORS AS MEDICINES FOR TREATING AIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-07-30 | — | — | WO | claimed |
| EP-0728481-A2 | Use of quinoxaline and protease inhibitors in a composition for the treatment of AIDS and/or HIV infections | BAYER AG (DE) | 1996-08-28 | — | — | EP | claimed |
| US-9107956-B2 | Oligomer-protease inhibitor conjugates | NEKTAR THERAPEUTICS (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2830629-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | Icahn School of Medicine Mount Sinai (US) | 2015-02-04 | — | — | EP | disclosed |
| US-20140045770-A1 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2013148197-A1 | COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20120108501-A1 | Protease Inhibitors | NEKTAR THERAPEUTICS (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110269677-A1 | Oligomer-Protease Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100124543-A1 | SULPHONAMIDE DERIVATIVES AS PRODRUGS OF ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100124543-A1 | SULPHONAMIDE DERIVATIVES AS PRODRUGS OF ASPARTYL PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-20 | — | — | US | disclosed |
| US-7592368-B2 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592368-B2 | Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070009593-A1 | Methods of treating cancer | Indianan University Advanced Research | 2007-01-11 | — | — | US | disclosed |
| US-20070009593-A1 | Methods of treating cancer | Indianan University Advanced Research | 2007-01-11 | — | — | US | disclosed |
| EP-0977570-A1 | QUINOXALINE IN TRIPLE COMBINATION WITH PROTEASE INHIBITORS AND REVERSE TRANSCRIPTASE INHIBITORS AS MEDICINES FOR TREATING AIDS | BAYER AG (DE) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998032442-A1 | QUINOXALINE IN TRIPLE COMBINATION WITH PROTEASE INHIBITORS AND REVERSE TRANSCRIPTASE INHIBITORS AS MEDICINES FOR TREATING AIDS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-07-30 | — | — | WO | disclosed |
| EP-0728481-A2 | Use of quinoxaline and protease inhibitors in a composition for the treatment of AIDS and/or HIV infections | BAYER AG (DE) | 1996-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070009593-A1 | Methods of treating cancer | CAPN2, CAPN9, CAPN1 | MLNR 3440/4885ABCB11 3462/4885LMNA 1278/4885 |
| US-20100124543-A1 | SULPHONAMIDE DERIVATIVES AS PRODRUGS OF ASPARTYL PROTEASE INHIBITORS | PRSS1, TMPRSS15, SI | MLNR 2865/4885ABCB11 549/4885LMNA 3813/4885 |
| US-20120108501-A1 | Protease Inhibitors | DNPEP, ADAM17, PREP | MLNR 692/4885ABCB11 658/4885LMNA 2367/4885 |
| US-20140045770-A1 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES | DNPEP, ADAM17, SERPINB1 | MLNR 302/4885ABCB11 373/4885LMNA 4161/4885 |
| US-20110269677-A1 | Oligomer-Protease Inhibitor Conjugates | ADAM17, DNPEP, SERPINB1 | MLNR 411/4885ABCB11 799/4885LMNA 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.